NHIA is working with the Department of Health and Human Services (HHS) to increase access to bamlanivimab (Eli Lilly) for COVID-19 in high-risk, eligible individuals residing or working in long-term care facilities, including assisted living facilities. The program utilizes home infusion providers – in partnership with facility staff – to identify, assess, coordinate, dispense, and administer monoclonal antibody therapies in these healthcare settings.
Through this pilot, NHIA is part of HHS’ Special Projects for Equitable and Efficient Distribution (SPEED) program.
Home infusion providers who wish to participate in the program and meet the eligibility criteria will be listed on a publicly accessible database for states to reference for future COVID-19 treatment opportunities.
The program is open to both NHIA member and non-member provider organizations, provided they qualify. In order to participate, a provider must:
To enroll in the pilot, home infusion providers will need to fill out an online application, sign a participation agreement, and return via email to email@example.com.
To access the full list of questions needed to complete the program application prior to filling it out, click below.
It is recommended to do this before proceeding with the application.
Hear from the NHIA team about the new NHIA Bamlanivimab Pilot Program, with information about the program and applicant requirements
on this on-demand webinar.
Bamlanivimab Pilot Program Office Hours
NHIA will host weekly office hours to answer questions about the newly launched Bamlanivimab Pilot Program. These calls will provide an opportunity for home infusion providers, facility staff, and other stakeholders to learn more about the program framework and goals. Sessions will be held weekly on Fridays at 10 a.m. Eastern Time. Relevant updates will be shared, and participants will be able to ask NHIA team members questions about the program.
The registration link below will sign you up for the series of office hours through the end of February – attending all sessions is not required.
To facilitate the efficient administration of COVID-19 vaccines to Skilled Nursing Facility (SNF) residents, CMS is exercising enforcement discretion with respect to statutory provisions requiring consolidated billing by SNFs as well as any associated statutory references and implementing regulations, including as interpreted in pertinent guidance. Through the exercise of this discretion, we will allow Medicare-enrolled immunizers working within their scope of practice and subject to applicable state law, including, but not limited to, pharmacies working with the United States, as well as infusion centers, and home health agencies, to bill directly and receive direct reimbursement from the Medicare program for vaccinating Medicare Part A SNF residents. This enforcement discretion, and accordingly the ability for entities other than the SNF to submit claims for these monoclonal antibody products and their administration furnished to Medicare Part A SNF residents, is limited to the period described in the above-cited enforcement discretion notice.